Gefitinib and Lapatinib treatment reduced tumor burden in Tpl2−/− mice by 88% and 50%, respectively, restoring tumor counts to Tpl2+/+ levels (Figure 3B,C). The gene discussed is MAP3K8; the disease is neoplasm.